Find Academic Supervisors

Caitriona M. O'Driscoll is Professor and Chair of Pharmaceutics at University College Cork's School of Pharmacy, Ireland. With over four decades of academic experience, she previously served as Head of the School of Pharmacy at UCC from 2003-2009 and 2010-2013. Her established drug delivery research team spans from pre-formulation through to production and manufacture of prototype delivery systems suitable for clinical trial, with strong industry links underpinning many research projects. Her research interests focus on translational drug delivery with emphasis on 'problem' drugs including poorly water soluble compounds and biopharmaceuticals like peptide/protein drugs, plasma DNA and siRNA. She develops nano-sized delivery constructs that are robust enough to survive processing, stable on storage, and achieve cell/site specific delivery in vivo. Greater than 40% of new chemical entities are poorly water soluble Biopharmaceuticals now approach 50% of all new drugs in development Major barrier is design of efficient delivery systems Special focus on oral drug delivery despite challenges Analysis of her recent publications reveals a strong emphasis on targeted nanodelivery systems for cancer therapy, particularly prostate and colorectal cancer, as well as neurodegenerative diseases like Huntington's. Her work demonstrates expertise in cyclodextrin-based nanoparticles, siRNA delivery, and disease-specific formulations that account for conditions like Crohn's disease that affect drug delivery. Scientific awards include: 'Person of the Year award' by Parenteral Drug Association (Ireland Chapter) in 2013 'Award for Professional Excellence' by Helix Health in 2007/2008 'Award for Pharmacist of the Year' by Helix Health in 2007/2008 With €10.5M in career research income and 25 PhDs graduated, Professor O'Driscoll's work has attracted funding from diverse sources including Science Foundation Ireland, Enterprise Ireland, and industry partners. Her research group maintains strong links with Pharmaceutical Chemistry and Process & Chemical Engineering at UCC, creating a unique strength for drug development research from design through to clinical trial. She has served as external examiner for multiple universities and as PhD thesis examiner at institutions worldwide. Her research team operates within UCC's drug delivery group, which has established expertise spanning from pre-formulation through to production and manufacture of prototype delivery systems. The group maintains strong industry connections and offers various PhD positions, focusing particularly on translational research with product-driven applications.

• Drug Delivery
• Pharmaceutics
• Nanomedicine
• +5 more

Philipp Neumann is a Professor and Chair of High-Performance Computing at Helmut Schmidt University since 2019. Previously, he held roles including Senior Researcher at the German Climate Computing Center (2016–2019), Postdoc at the University of Hamburg (2017–2019), and completed his Habilitation in Scientific Computing at TU Munich (2019). He transitioned to DESY/Universität Hamburg in May 2024. Education : PhD (Dr. rer. nat.) in Scientific Computing at TU Munich (2008–2013) Habilitation in Scientific Computing at TU Munich (2019) Studies in Technomathematics at Friedrich-Alexander University Erlangen-Nuremberg (2003–2008) Research Interests focus on high-performance computing, parallel and distributed systems, computational science, and applications in climate modeling. His work bridges computational methods with medical challenges, including surgical simulation training, wound healing mechanisms, and gastrointestinal pathology. Professional Activities include leadership roles in major conferences such as steering committee member for ISPDC (since 2021) and program committee roles in IPDPS, ICCS, and IEEE Cluster. He also managed the DFG priority program SPPEXA (2013–2016). Labs/Teams include the Chair for High-Performance Computing at Helmut Schmidt University and collaborations with the German Climate Computing Center. His current work at DESY/Universität Hamburg likely expands these computational efforts into interdisciplinary research.

• High-Performance Computing
• Scientific Computing
• Parallel and Distributed Systems
• +4 more

Frida Hållenius is an Associate Professor and Senior Lecturer in Molecular Nutrition at the Division of Food and Pharma, Faculty of Engineering (LTH), Lund University. She is a key member of the LTH Profile Area: Food and Bio and leads or actively participates in multiple research projects exploring the role of diet and gut microbiota in human health. Associate Professor in Molecular Nutrition Senior Lecturer, Division of Food and Pharma Faculty of Engineering (LTH), Lund University Principal Investigator, Gut Microbiome Laboratory (GML) Active researcher in 3 ongoing projects, including NeuroFood and ScanOats Her research is centered on host-microbiota interactions, particularly how dietary components, probiotics, and polyphenols influence gut health, inflammation, metabolic diseases, and neuroinflammation. Her work bridges nutrition, microbiology, and neuroscience, with a strong focus on preventive strategies for lifestyle-related diseases such as obesity, diabetes, and Alzheimer’s disease. She employs both animal models (e.g., C57BL/6, Apoe-/- mice) and human-relevant in vitro systems to study dietary interventions. The recent trends in her publications highlight a strong focus on the gut-brain axis, the impact of Nordic berries and legumes on microbiota and metabolic health, and the use of advanced models like 3D intestinal tissue. Her work often involves interdisciplinary collaboration and contributes to multiple UN Sustainable Development Goals, particularly those related to good health and well-being. Scientific Awards: No specific awards mentioned in the provided text. She has supervised several junior researchers and students, including research students and assistants, and is actively involved in grant-funded research projects from FORMAS and private foundations. She leads the Gut Microbiome Laboratory (GML), a collaborative research environment focused on understanding how diet shapes the gut microbiome and influences disease pathways. Her leadership in projects like NeuroFood and those targeting Alzheimer’s disease underscores her commitment to translational nutritional science.

• Molecular Nutrition
• Host-Microbiota Interactions
• Gut Health
• +12 more

Lieuwke Kranenburg is an Assistant Professor at the Faculty of Veterinary Medicine , Utrecht University , specializing in Equine Internal Medicine . She provides patient care at the University Equine Clinic and teaches Master's courses in equine digestion , infectious diseases , and skin problems . Research Focus: Equine internal medicine, digestive diseases, infectious pathogens, metabolic disorders Professional Certifications: EBVS® European Veterinary Specialist in Equine Internal Medicine International Collaboration: Trained Chinese veterinarians at Heilan Equestrian Centre Publications highlight her work on equine gastric disease management, diagnostic imaging, infectious disease epidemiology, and metabolic research. She contributes to equine clinical research through peer-reviewed journals and conference abstracts. Professional Involvement: Former board member of the Equine Medicine Group and current GGP representative for FEEVA, maintaining professional networks and advancing equine veterinary practice.

• Equine Internal Medicine
• Equine Digestive Diseases
• Infectious Diseases in Horses
• +6 more

Dr. Oluwabunmi (Bunmi) Olaloye is an Assistant Professor of Pediatrics in the Division of Neonatology at Yale School of Medicine. She holds appointments in Neonatal-Perinatal Medicine and is affiliated with the Janeway Society. Her academic background includes an MD from Rutgers New Jersey Medical School, pediatrics residency at University of Texas Medical Branch, and neonatology fellowship at University of Pittsburgh Medical Center. Dr. Olaloye's research focuses on immune dysfunction underlying neonatal intestinal diseases such as necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP). Using cutting-edge techniques like single-cell RNA sequencing and mass cytometry, her work identifies biomarkers and therapeutic targets to improve outcomes for premature infants. Key research areas include fetal immune system maturation, placental immune interactions, and gestational age-specific inflammatory responses. Her publication record spans 12 peer-reviewed articles between 2019-2025, emphasizing translational immunology and neonatal pathophysiology. Notable contributions include defining immune cell trajectories in preterm infants and developing gating guidelines for high-dimensional cytometry data. Current projects involve constructing immune cell atlases across human lifespans and investigating nutritional interventions for intestinal disorders. Laboratory affiliations include the Laboratory for Surgery, Obstetrics & Gynecology where she explores neonatal mucosal immunity. Her work integrates clinical observations with systems immunology approaches to address critical gaps in understanding prematurity-associated gastrointestinal pathologies.

• Neonatology
• Immunology
• Pediatric Gastroenterology
• +3 more

Katherine Elizabeth Chetta, M.D., serves as an Assistant Professor of Pediatrics in the College of Medicine at the Medical University of South Carolina (MUSC), practicing neonatology at Shawn Jenkins Children's Hospital in Charleston. Her clinical focus centers on critically ill newborns in the Neonatal Intensive Care Unit (NICU), with specialized expertise in preterm infant care and nutritional management. Dr. Chetta completed her educational journey with a B.S. in Chemistry (Honors) from the University of Kansas (2005), followed by her M.D. from Baylor College of Medicine (2009) where she earned Alpha Omega Alpha (AOA) distinction and High Honors. She completed Pediatrics Residency (2013) and Neonatology Fellowship (2016) at Baylor College of Medicine and the University of Texas Health & Science Center in Houston. Her research program investigates critical aspects of neonatal nutrition, particularly the biochemical properties of human milk and its role in preventing gastrointestinal disorders. Key focus areas include necrotizing enterocolitis (NEC) pathogenesis, free fatty acid metabolism in preterm milk, maternal vitamin D impacts on infant immunity, and quality improvement initiatives for human milk utilization. Collaborations span the Digestive Disease Research Center Core and Darby Children's Research Institute at MUSC, integrating laboratory science with clinical epidemiology. Analysis of her 15 most recent publications reveals dominant research trajectories: (1) Human milk composition and storage effects on infant outcomes, (2) NEC risk stratification through clinical/laboratory markers and imaging, (3) Social determinants of growth in preterm infants, and (4) Microbiome interactions with milk components. Her work bridges basic science (in vitro cytotoxicity studies) with clinical implementation (NICU quality improvement). Scientific recognition includes: Induction into Alpha Omega Alpha (AOA) Honor Medical Society Dr. Chetta actively collaborates with multidisciplinary teams across MUSC's research infrastructure, though specific grant details aren't provided in source materials. Her mentorship extends to medical trainees within the neonatology division, focusing on translational research methodologies. Current projects emphasize standardizing NEC diagnostic protocols and optimizing human milk feeding systems for vulnerable infants. She contributes to laboratory-based investigations at the Darby Children's Research Institute, particularly studying HAMLET complexes in human milk and their effects on intestinal cell metabolism. Her clinical work directly informs ongoing quality improvement initiatives aimed at increasing mother's own milk usage rates in the NICU.

• Neonatology
• Preterm Infant Nutrition
• Necrotizing Enterocolitis
• +3 more

Professor Mark Morrison is an Affiliate Professor at the School of Chemistry and Molecular Biosciences, University of Queensland, and holds roles as Chair & Group Leader of Metagenomics at the Frazer Institute within the Faculty of Health, Medicine and Behavioural Sciences. His research focuses on clinical microbiology, gastroenterology, and the microbiome’s role in diseases like inflammatory bowel disease (IBD) and diabetes. He has extensive academic qualifications, including a Bachelor of Science from the University of New South Wales, a Master’s from James Cook University, and a PhD from the University of Illinois. Education : Bachelor of Science, University of New South Wales Masters (Research) of Science, James Cook University Doctor of Philosophy, University of Illinois His research interests span microbiome-driven health and disease mechanisms, particularly in gut-brain interactions, mucosal microbiota dynamics, and translational therapies. Over 390 works include studies on dietary FODMAP effects, microbiome-based IBD diagnostics, and SCFA therapy for diabetes. He leads interdisciplinary grants on microbiome manipulation and has advised numerous PhD students on topics like Crohn’s disease, archaeal biodiversity, and immune modulation. His recent articles highlight microbiota roles in SIBO, anastomotic leaks, and probiotic efficacy. While no explicit awards are cited, his contributions to gut microbiome science are recognized through active research collaborations and funding. He actively supervises students and chairs teams advancing metagenomics and clinical applications.

• Biomedical and Clinical Sciences
• Clinical microbiology
• Gastroenterology and hepatology
• +3 more

Allan B. Dietz is a Professor of Laboratory Medicine and Pathology at Mayo Clinic College of Medicine and Science. He serves as Co-Director of the Human Cellular Therapy Lab at Mayo Clinic's Center for Regenerative Biotherapeutics, with dual appointments in the Department of Immunology and Division of Transfusion Medicine. 1986: BA in Biology and Chemistry from University of Northern Iowa 1992: PhD in Genetics from Texas A&M University 1993: Postdoctoral Fellowship at USDA Agricultural Research Service His research spans cellular immunotherapy, stem cell biology, and regenerative medicine , with a focus on dendritic cell vaccines for cancers (CML, melanoma, glioblastoma), monocyte immunosuppression mechanisms, and mesenchymal stromal cell applications in GVHD and tissue repair (ALS, Crohn’s, renal stenosis, diabetes). Recent work includes microfluidic bioreactor development for cell therapy manufacturing and immune profiling for cancer patients. Key publications from 2024-2025 include: Microfluidic bioreactors for dendritic cell production Pembrolizumab-ibrutinib melanoma trials Mesenchymal stem cells in spinal cord injury Multiorgan transplant immune management guidelines Awarded: 2017 Mayo Clinic Team Science Award 1997 Voyles Fellowship in Stem Cell Biology 1991 Carrington Award for Cell Biology Active in regulatory committees including FDA-compliant cell therapy oversight and ISCT North American meetings. Integrates laboratory findings with clinical workflows through Mayo Clinic's CCaTS and Center for Individualized Medicine programs.

• Cellular Immunotherapy
• Stem Cell Biology
• Cancer Vaccines
• +5 more

Thomas Pap serves as Professor at the Department of Molecular Medicine within the Institute of Musculoskeletal Medicine (IMM) at the University of Muenster. He actively participates in the "Cells in Motion" research cluster and the Imaging Network, focusing on cell dynamics and imaging applications in musculoskeletal pathologies. His research centers on molecular mechanisms of inflammatory joint diseases, with key emphases on: Destructive arthritis pathogenesis through fibroblast transformation and adherens junction dynamics Regulation of alarmin activity (S100A8/S100A9) in sterile inflammation TRP channel modulation of osteoclast function and bone loss Translational models for tendon healing and microsurgical reconstruction Advanced imaging techniques for monitoring inflammatory lesions Analysis of his 2013-2021 publications reveals consistent interdisciplinary work bridging immunology, cell biology, and clinical applications. His studies frequently employ molecular imaging and translational models to investigate rheumatoid arthritis mechanisms, neutrophil chemotaxis, and bacterial immune evasion, with strong emphasis on therapeutic targeting of inflammatory pathways. The Pap Group operates within the Multiscale Imaging Centre (MIC), collaborating on pilot projects and the "Train Gain Fellowships" graduate program. Their work integrates with the university's broader Imaging Network, utilizing advanced microscopy and molecular techniques to study cell dynamics in inflammatory conditions.

• Rheumatology
• Inflammation
• Arthritis
• +4 more

Jan Olav Høgetveit is an Associate Professor in the Department of Physics at the University of Oslo (UiO), within the Faculty of Mathematics and Natural Sciences. He also serves as Head of Research & Development in the Department of Biomedical and Clinical Engineering at Rikshospitalet, Norway’s national hospital. His work bridges physics and clinical practice, focusing on medical instrumentation. Education: Bachelor of Electronic Engineering (Technical Cybernetics), Oslo University College, 1993 Master of Electronics, University of Oslo (Department of Physics), 1997 Ph.D. in Physics (Technology Applications for Medical Devices), University of Oslo, 2008 Research Interests: Høgetveit specializes in biomedical instrumentation and clinical engineering, particularly in surgical technology and wireless communication impacts on medical devices. His work addresses challenges like real-time physiological monitoring during heart-lung machine use, non-invasive blood glucose detection, and bioimpedance-based viability assessment of organs. He emphasizes interdisciplinary collaboration between engineering and medicine to enhance patient safety and surgical outcomes. Scientific Contributions: His research trends span bioimpedance applications in ischemia/reperfusion injury, machine learning for surgical decision support, and electrosurgery safety. He has explored ventilator optimization during pandemics and implant-related thermal risks. Contributions highlight both hardware development (e.g., optically isolated current sources) and software innovations (e.g., neural networks for viability prediction). Awards: No scientific awards explicitly mentioned in the text. Advising & Grants: Høgetveit received a 1998–2001 research council scholarship. As Head of R&D since 2001, he oversees translational projects. No formal advisees/students listed, though he collaborates extensively with teams on device development and clinical trials. Labs & Teams: Affiliated with UiO’s Department of Physics and Rikshospitalet’s Biomedical and Clinical Engineering department. Active in the Electronics research group at UiO. Engages with multidisciplinary teams addressing surgical instrumentation and physiological monitoring challenges.

• Biomedical Instrumentation
• Medical Technology
• Clinical Engineering
• +3 more

Prof. Fahrettin Yıldız is a full-time Professor at Gaziantep University's Faculty of Medicine, Department of General Surgery, specializing in hepatobiliary surgery, organ transplantation, and ischemia-reperfusion pathology. He completed his medical degree at Ege University Faculty of Medicine (1993-1999) and surgical specialization at Aegean Medical Faculty (2012-2016). His academic career includes promotions from Assistant Professor to Professor through positions at Harran University and Gaziantep University. Research interests span: Transplant Surgery : Innovations in living-donor techniques for liver/kidney transplantation Ischemia-Reperfusion Injury : Protective effects of flavonoids, herbal agents (Nigella sativa), and amino acids Minimally Invasive Approaches : Laparoscopic techniques for appendectomy/cholecystectomy Surgical Oncology : Management of breast, gastric, and pancreatic malignancies His publications demonstrate a strong focus on experimental and clinical surgery, with recurring themes in oxidative stress mitigation, novel anastomosis techniques, and management of surgical complications. Recent work (2024) addresses persistent biliary fistulas, while transplantation-related studies explore biomarkers for graft survival. Prof. Yıldız has supervised 5 medical specialization theses and actively contributes to national/international surgical societies including the Turkish Organ Transplantation Coordination Association and Liver Transplantation Association. He maintains involvement in ongoing research on SGLT2 inhibitors in transplant recipients and laparoscopic donor nephrectomy outcomes.

• Hepatobiliary Surgery
• Organ Transplantation
• Ischemia-Reperfusion Injury
• +4 more

Alex Banks is an Assistant Professor at Harvard Medical School and Beth Israel Deaconess Medical Center (BIDMC), with a focus on metabolic disorders. As Director of the Energy Balance core facility at BIDMC, he employs indirect calorimetry to study energy expenditure, food intake, and thermogenesis in mice. His research bridges genetic, pharmacological, and environmental factors to enhance understanding of obesity and metabolic diseases, while developing open-source tools like CalR to standardize metabolic analysis for the broader scientific community. Role: Assistant Professor Affiliation: Harvard Medical School, BIDMC Facility: Energy Balance Core Director Research Interests: The Banks Lab investigates mechanisms of obesity and metabolic disorders, emphasizing energy balance regulation through: Indirect calorimetry and metabolic rate analysis Genetic and pharmacological modulation of PPARγ Gut microbiome interactions with host metabolism Neural circuits controlling thermogenesis and food-seeking behavior Development of computational tools (CalR) for metabolic data Scientific Trends: Recent work spans obesity-linked phosphorylation of PPARγ, thermogenesis regulation via thyroid hormone, microbiome-dependent metabolic control, and novel methods for calorimetry. Collaborative projects address translational applications in bariatric surgery and metabolic drug development. Collaborations: The lab serves as a hub for Harvard/Boston-area researchers and provides freely accessible analytical tools to maximize utility of animal and human studies in combating obesity.

• Metabolic Disorders
• Energy Balance
• Obesity
• +6 more

Ian Carroll, PhD is an Associate Professor in the Department of Nutrition at the UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill. His research focuses on gastrointestinal biology and disease, with specific expertise in microbiome interactions. He directs the Carroll Lab and holds affiliations with the Center for Gastrointestinal Biology and Disease (CGIBD), where he serves as a Microbiome Focus Area investigator. Dr. Carroll's research centers on mechanisms through which intestinal microbiota and their metabolites influence gastrointestinal physiology, behavior, and weight regulation. His work spans microbiome dynamics in obesity, diabetes, and eating disorders , with particular emphasis on short-chain fatty acid physiology , gut-brain axis communication , and nutritional interventions . His laboratory has pioneered techniques for biological sample collection and bacterial DNA isolation from human fecal and mucosal samples. His publication trends reveal strong focus on Microbiome responses to dietary interventions (fiber, almonds, purified diets) Longitudinal biomarker discovery using interpretable machine learning Clinical applications in hypertension, bariatric surgery, and anorexia nervosa Cross-species validation through murine models Award Highlights: CGIBD Pilot and Feasibility Award (2012) Dr. Carroll maintains active collaborations across multiple disciplines including gastroenterology, immunology, and computational biology. His work integrates molecular techniques with clinical studies to develop nutritional therapies for gastrointestinal diseases. Current research examines microbial contributions to weight regulation post-bariatric surgery and mechanisms underlying microbiome-mediated blood pressure control. The Carroll Lab operates within the MBRB building facility, conducting translational research bridging basic microbial science with clinical applications in metabolic and gastrointestinal disorders.

• Microbiome Research
• Gut-Brain Axis
• Nutritional Therapies
• +3 more

Maria dos Santos Lonsdale serves as Professor of Information and Communication Design at the University of Leeds School of Design, where she also directs PACE (Professional Academy for Creative Enterprise) and previously served as Head of School from 2020 until her current sabbatical through September 2026. With academic credentials including a PhD from the University of Reading (2006) and extensive teaching experience since 1997 across Portugal and the UK, she brings significant expertise to her roles. Her research demonstrates remarkable interdisciplinary breadth, spanning healthcare communication, cybersecurity awareness, educational technology, and sustainable fashion. Lonsdale employs rigorous user-centered methodologies including focus groups, co-design sessions, usability testing, and eye-tracking studies to validate design solutions that improve user performance and wellbeing. Her work consistently bridges theoretical research with practical applications across multiple sectors. Lonsdale holds influential editorial positions as Editor-in-Chief for Visible Language journal (starting January 2025) and former Editor-in-Chief (2020-2024) for the Information Design Journal. She actively contributes to the academic community as an Academic Advisor for Luto (a global health communications company) and as a reviewer for major publishers including Sage and Routledge. Senior Fellow of the Higher Education Academy (SFHEA) Member of the International Society of Typographic Designers (MISTD) Regular contributor to design research societies Her research output reveals consistent focus on making information accessible and usable across diverse contexts, from virtual learning environments to public health communications. Lonsdale's work demonstrates how thoughtful application of design principles can solve complex real-world problems while enhancing user experience and information comprehension.

• Information Design
• Communication Design
• Typographic Design
• +7 more

Dr. Jeffrey D. Punch is the Jeremiah and Claire Turcotte Professor of Surgery at the University of Michigan Medical School. He specializes in liver, pancreatic, and kidney transplantation for adults and children, as well as vascular surgery for dialysis access. He serves as Director of the Liver Transplant Program and performed Michigan's first living donor liver transplant in 1996. His clinical interests include immunosuppression management and organ tolerance. He is board-certified in General Surgery and Surgical Critical Care. Education & Training: MD from University of Michigan Medical School (1986) Residency in General Surgery at University of Michigan Health System (1992) Fellowship in Surgical Transplantation at University of Michigan (1994) Research & Service: Dr. Punch leads clinical research studies on transplant recipients and has held roles including: Member, Liver and Intestinal Committee, United Network for Organ Sharing Former Board Director, United Network for Organ Sharing Former President, Gift of Life Michigan Professional Affiliations: Fellow of the American College of Surgeons.

• Transplant Surgery
• Surgical Critical Care
• Immunosuppression Management
• +3 more